| Date |
Title |
|
|
November 8, 2024
|
Fulgent Reports Third Quarter 2024 Financial Results
|
|
|
November 5, 2024
|
Fulgent to Participate in Upcoming Conferences
|
|
|
October 31, 2024
|
Fulgent Genetics Awarded Contract by the U.S. Department of Veterans Affairs to Provide Hereditary Cancer, Pharmacogenetic and Other Genetic Testing to Veterans¹
|
|
|
October 17, 2024
|
Fulgent to Announce Third Quarter 2024 Financial Results on Friday, November 8, 2024
|
|
|
August 2, 2024
|
Fulgent Reports Second Quarter 2024 Financial Results
|
|
|
July 11, 2024
|
Fulgent to Announce Second Quarter 2024 Financial Results on Friday, August 2, 2024
|
|
|
June 3, 2024
|
Fulgent Data at ASCO 2024 Highlights Antitumor Activity from Lead Therapeutic Oncology Candidate, FID-007, in Head and Neck Cancer
|
|
|
May 24, 2024
|
Fulgent Announces Upcoming Presentation of Clinical Data for Its Lead Therapeutic Oncology Candidate, FID-007, at ASCO 2024 Annual Meeting
|
|
|
May 14, 2024
|
Moffitt Cancer Center and Fulgent Pharma Join Forces to Revolutionize Cancer Therapeutics
|
|
|
May 3, 2024
|
Fulgent Reports First Quarter 2024 Financial Results
|
|
|
April 11, 2024
|
Fulgent Genetics to Announce First Quarter 2024 Financial Results on Friday, May 3, 2024
|
|
|
February 28, 2024
|
Fulgent Reports Fourth Quarter and Full Year 2023 Financial Results
|
|
|
February 13, 2024
|
Fulgent Genetics to Announce Fourth Quarter and Full Year 2023 Financial Results on Wednesday, February 28, 2024
|
|
